David Greeley, MD
Neurology · Spokane, WANPI 1386758712
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Eisai Inc. at 33.2% of the total. Reporting peaked in 2023 at $10,922 and has fallen 53.5% since, to $5,081 in 2025. Among neurology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 938 payments — averaging $41.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$13K
- Biogen$7K
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Ipsen Innovation$2K
- Lilly USA, LLC$1K
- plus $11K from 50 others
Across 75 payments — averaging $112,644 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$7M
- Eli Lilly$1.1M
- Eisai Inc.$214K
- Merz North America, Inc.$52K
- Teva Pharmaceuticals USA, Inc.$22K
- Genentech, Inc.$14K
- plus $15K from 3 others
What the payments were for
- Consulting fees$16,44543%
- Speaking & faculty fees$2211%
- Travel & lodging$2,1466%
- Food & beverage$19,76251%
- Education$1050%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,679 in reported general payments places this provider in the 90th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 35 | $43,632 |
| UbrelvyUbrogepant | 18 | $26,767 |
| RexultiBrexpiprazole | 12 | $17,756 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $17,198 |
| QuliptaAtogepant | 11 | $13,200 |
| Emgality PenGalcanezumab-Gnlm | 12 | $10,183 |
| Rasagiline Mesylate | 51 | $6,108 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 169 | $3,736 |
| Rivastigmine | 23 | $2,509 |
| Donepezil Hcl | 180 | $1,929 |
| Quetiapine Fumarate | 35 | $1,403 |
| Memantine Hcl | 58 | $1,318 |
| Selegiline Hcl | 13 | $1,066 |
| Ropinirole Hcl | 19 | $956 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 34 | $897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $224 | $43,63235 claims |
| AbbVieUbrelvy, Qulipta | $3,035 | $39,96729 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $260 | $17,75612 claims |
| Upsher-smith Laboratories LLCTopiramate | $200 | $15218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 neurology providers in Washington.
Other neurology in Spokane
- Jason AldredSpokane$1M
- Jessica CraddockSpokane$266K
- Steven PughSpokane$162K
- Luis ParySpokane$64K
- Pavle RepovicSeattle$1.1M
- Pinky AgarwalKirkland$795K
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.